

Respiratory Medicine

NZ Clinical Trial Showcase

Richard Beasley

Director, Medical Research Institute of New Zealand

Physician, Capital & Coast District Health Board

Respiratory Research

- Asthma
- COPD
- Respiratory infections
- Obstructive sleep apnoea
- Critical care
- Lung cancer
- Paediatrics

- Auckland:** Innes Asher, Ed Mitchell, Cass Byrnes,
Marg Wilsher, Robert Young
- Middlemore:** Jeff Garrett, Harry Rea, Lata Jayaram,
Conroy Wong, Andrew Veale
- Waikato:** Noel Karalus, Graham Mills, Bob Hancox
- Tauranga:** Neil Graham, Shaun Holt
- Wellington:** Kyle Perrin, Julian Crane, Philippa
Gander, Alister Neill, Paul Young
- Christchurch:** Mike Epton, Richard Lang, Lutz Beckert
- Dunedin:** Robin Taylor, Bob Hancox

Industry-funded trials

Aradigm

AstraZeneca

Baxter

Bayer

Boehringer Ingelheim

Cephalon

Chiesi

Fisher & Paykel Healthcare

GlaxoSmithKline

Intermune

Levana

Lilly

Merck

Nexus6 Ltd

Novartis

Novotech

Pharmaxis

Roche

Sanofi-Aventis

Schering Plough

“Real life use of Symbicort ‘SMART’ regime in adult asthma”

- **300 adults with severe asthma**
- **Symbicort SMART vs standard regimes**
- **Electronic actuation monitors to assess use (Nexus6 Ltd)**
- **28 week RCT**

SMART

CLINICANZ

- **Site management organisation**
- **Train GPs in clinical trials**
- **25 GPs, 300,000 patients**
- **Auckland and Tauranga**

Randomised placebo-controlled trial of paracetamol use in influenza

- **80 subjects, proven influenza**
- **MRINZ / CCDHB / ESR / Canterbury Medical Laboratories**
- **Effect on clinical severity and viral shedding**
- **CTU, 14-bed inpatient facility**

Pharmacotherapy for different phenotypes of airways disease

Phase 1: Postal survey 9,000 adult subjects
randomly selected, electoral roll

Phase 2: Detailed investigations 450 subjects

Phase 3: Responsiveness to specific treatments

Pharmacotherapy for different phenotypes of airways disease

- **Collaborative study with China**
- **Professor Chen Wang, Beijing Hospital**
- **AstraZeneca Ltd, Sweden**

Randomised placebo-controlled trial of paracetamol in febrile septic patients

- **MRINZ / CCDHB / 6 ICUs NZ / 2 ICUs Australia**
- **700 critically ill patients**
- **Australia & New Zealand Intensive Care Society (ANZICS)**

ANZICS Clinical Trials Group

- A combined research program of more than 70 studies
- \$40 million in competitive grant funding
- 19,000 patients randomised into trials
- Over 60 peer-reviewed publications,
including 5 in the *New England Journal of Medicine*

[ANZICS 2010 Annual Report]

Bronchodilator duration of action

- **CTU facility**
- **Investigator-driven**
- **24 hour bronchodilator duration of action**
- **Salmeterol (adults and children)**
- **Formoterol (adults)**

Alternative / Complementary treatments

- **Shaun Holt / Clinicanz**
- **Kanuka honey – medical grade products**
- **Eczema, MRSA ...**
- **GP network**

Respiratory research in NZ

- **Strong productive research groups**
- **Experienced senior investigators**
- **Broad interests, children & adults**
- **Existing relationships with industry**
- **Good clinical practice**

Respiratory research in NZ

- **Community links – recruitment**
- **Collaboration – multidisciplinary**
- **Collaboration – international**
- **Investigator-driven**